Streetbeat News

Price Targets

FIVE

Telsey Advisory Group analyst Joseph Feldman has maintained an 'Outperform' rating on Five Below (NASDAQ:FIVE) but lowered the price target from $225 to $220.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 9:07 am

ETN

HSBC analyst Puneet Garg maintains a Hold rating on Eaton Corp (NYSE:ETN) and raises the price target from $161 to $210.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:59 am

CHWY

Barclays analyst Trevor Young has maintained an Equal-Weight rating on Chewy (NYSE:CHWY) but lowered the price target from $35 to $28.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:56 am

PSTG

Barclays analyst Tim Long has maintained an Overweight rating on Pure Storage (NYSE:PSTG) and raised the price target from $38 to $42.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:56 am

VSTA

JP Morgan analyst Marcelo Santos has upgraded Vasta Platform (NASDAQ:VSTA) from Neutral to Overweight and announced a price target of $5.5.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:52 am

TSX:FDY

Stifel analyst Alex Terentiew has initiated coverage on Faraday Copper (TSX:FDY) with a Buy rating and a price target of C$1.5.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:46 am

CRNX

Oppenheimer analyst Leland Gershell has initiated coverage on Crinetics Pharmaceuticals with an Outperform rating and a price target of $40.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:29 am

TNP

Jefferies analyst Omar Nokta has reiterated a 'Buy' rating on Tsakos Energy Navigation (NYSE:TNP) and maintained a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:21 am

GOVX

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a 'Buy' rating on Geovax Labs (NASDAQ:GOVX) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:19 am

PPBT

HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Purple Biotech (NASDAQ:PPBT) and raises the price target from $7 to $9.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:18 am